I samband med Bengt Dahlströms 65 årsdag i mars utsågs Anders Millerhovf, som är en av medgrundarna till bolaget, till ny VD. Bengt Dahlström kommer att fortsätta som styrelsens ordförande och parallellt arbeta som Chief Scientific Officer med utveckling av företagets specialistfunktioner och strategiska utveckling.
Läs mer om det på denna länken,
Akademiska sjukhuset och Uppsala universitet är först i Sverige med en integrerad PET/MR-kamera som avbildar kroppen på olika sätt. Att kunna samla in data från båda teknikerna samtidigt underlättar diagnostik och ger mer kunskap om effekten av olika behandlingar vid till exempel hjärt- kärlsjukdomar, cancer och neurologiska sjukdomar.
STOCKHOLM, SWEDEN – October 21, 2014. Athera Biotechnologies AB, a Karolinska Development
AB portfolio company, today announced that first dosing of healthy volunteers has been done in a Phase I study of its fully human antibody PC-mAb. This lead product candidate targets the inflammatory component of cardiovascular disease, where current therapies are considered to be inadequate.
“We are pleased to have executed our plans in a very timely manner and are looking forward to the results from this important first clinical trial with our PC-mAb” says Carina Schmidt, CEO of Athera. “This is a key achievement for the EU FP7 project CARDIMMUN, aiming to generate proof-of-activity data for PC-mAb.”
“I am delighted to see this pharmaceutical project for such life threatening conditions leaving the lab benches to enter clinical trials”, says Bruno Lucidi, CEO of Karolinska Development.
Athera’s fully human monoclonal antibody PC-mAb is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death. It is known from previous published studies that low plasma levels of endogenous antibodies against phosphorylcholine (anti-PC) are linked to poor prognosis in acute heart attack patients, as well as in patients with peripheral arterial disease undergoing vein graft surgery. The current Phase I study will include up to 48 healthy volunteers in a single ascending dose protocol with safety outcome measures and is performed in Uppsala by CTC Clinical Trial Consultants AB. The development costs for Athera’s lead product candidate are co-financed by the EU FP7 program, within the project CARDIMMUN.
Bioneer, BioAdvice, Recipharm and CTC Clinical Trial Consultants are all involved in numerous early development projects and have broad experience both regarding product applications and development technologies. Together these four Scandinavian companies offer a set of services that will help you to get through the challenging phase of early drug development. In this half day meeting, we will present our view on how to work in an efficient work-flow with a minimum of efforts to perform the needed work. If you are interested please contact firstname.lastname@example.org for an invitation.
Meet us in Solna / Stockholm 1 October 2014
Meet CTC at the National Lice Science Day, 30 Sep 2014. Tina Nordén and Anders Millerhovf from CTC will attend.
Thanks to SwedenBIO, the Swedish Life science Industry Organistaion in cooperation with Oslo Cancer Cluster and Toulouse Cancer-Bio-Santé Cluster for an excellent event. We meet many new interesting clients and potential busniess partners.
- Bengt Dahlström, Tina Norden, Anders Millerhovf and Cornelia Tiberg at CTC Clinical Trial Consultatns AB
Today we are releasing our new and updated webiste, some links will be updated with more information during the summer.
Cornelia Tiberg, MD will start at CTC 2014-Jun-09